|This Slide: #49 of 100|
Slide #49. Aratana Therapeutics — Okapi Sciences NV
Aratana Therapeutics (PETX)
Okapi Sciences NV
Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has acquired Okapi Sciences NV, a Belgium-based company with a proprietary pet therapeutics antiviral platform and five clinical/development stage candidates for treating important viral diseases. The strategic acquisition of Okapi further enhances Aratana's leadership position in pet therapeutics by bringing with it a unique combination of individuals, strong relationships with academic institutions, novel technologies and products, and favorable geographic location. Aratana plans to continue to advance the current Okapi pipeline of high value antiviral drugs, including its feline herpes and feline immunodeficiency virus franchises.
Aratana Therapeutics is a pet therapeutics company that licenses, develops and commercializes therapeutics for dogs and cats. At Dec 31 2017, Co.'s portfolio included multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and molecule biologics. Co. has three U.S. Food and Drug Administration approved therapeutics: GALLIPRANT® (grapiprant tablets) for the control of pain and inflammation associated with osteoarthritis in dogs; ENTYCE® (capromorelin oral solution) for appetite stimulation in dogs; and NOCITA® (bupivacaine liposome injectable suspension) as a local post-operative analgesia for cranial cruciate ligament surgery in dogs.
Open the PETX Page at The Online Investor »
Free PETX Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Hold (2.00 out of 4)
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite